Research and experimental development on natural sciences and engineering
VAXXINOVA NORWAY AS
Revenue 2025
NOK 17.7m
Operating profit
NOK −35.5m
Equity
NOK 893,000
Incorporated
2010
Employees
23
Share capital
NOK 100,000
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2025 | Trend |
|---|---|---|
| Total operating revenue | 17.7m | |
| Total operating costs | 53.2m | |
| Operating profit (EBIT) | −35.5m | |
| Net financial items | 3.1m | |
| Profit for the year | −24.6m |
Balance sheet
| Post | 2025 | Trend |
|---|---|---|
| Total assets | 78.7m | |
| of which current assets | 25.2m | |
| Equity | 893k | |
| Total liabilities | 77.8m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.